FGF23 induces left ventricular hypertrophy

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369

Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology

Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart study

Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699

Prevalence of Chronic Kidney Disease in the United States

Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837

A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy

Molkentin, J. D., Lu, J., Antos, C. L., Markham, B. E., Richardson, J. A., Robbins, J. M., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566

Fibroblast growth factors.

Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 1,985

Cellular signaling by fibroblast growth factor receptors

Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,923

Regulation of cardiac hypertrophy by intracellular signalling pathways

Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,890

Receptor Specificity of the Fibroblast Growth Factor Family

Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., & Goldfarb, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15292 · Cited by 1,871

Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?

Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782

The Fibroblast Growth Factor signaling pathway

Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050

KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD

Inker, L. A., Astor, B. C., Fox, C. H., Isakova, T., Lash, J. P., Peralta, C. A., Tamura, M. K., & Feldman, H. I. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.01.416 · Cited by 1,828

Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association

Rangaswami, J., Bhalla, V., Blair, J. E., Chang, T. I., Costa, S. P., Lentine, K. L., Lerma, E. V., Mezue, K. N., Molitch, M. E., Müllens, W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000664 · Cited by 1,535

The Osteocyte: An Endocrine Cell … and More

Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1026 · Cited by 1,042

The Klotho proteins in health and disease

Kuro-o, M. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0078-3 · Cited by 707

Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease

Matsushita, K., Ballew, S. H., Wang, A. Y.-M., Kalyesubula, R., Schäeffner, E., & Agarwal, R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00616-6 · Cited by 728

Nutritional Management of Chronic Kidney Disease

Kalantar-Zadeh, K., & Fouque, D. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1700312 · Cited by 636

Fibroblast Growth Factor 23 and Klotho: Physiology and Pathophysiology of an Endocrine Network of Mineral Metabolism

Hu, M. C., Shiizaki, K., Kuro-o, M., & Moe, O. W. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183727 · Cited by 587

Cardiovascular disease in dialysis patients

Cozzolino, M. G., Mangano, M., Stucchi, A., Ciceri, P., Conte, F., & Galassi, A. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy174 · Cited by 576

Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy

Grabner, A., Amaral, A. P., Schramm, K. J., Singh, S., Sloan, A. J., Yanucil, C., Li, J., Shehadeh, L. A., Hare, J. M., David, V., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.09.002 · Cited by 561

Effects of Phosphate Binders in Moderate CKD

Block, G. A., Wheeler, D. C., Persky, M. S., Kestenbaum, B. R., Ketteler, M., Spiegel, D. M., Allison, M., Asplin, J. R., Smits, G., Hoofnagle, A. N., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012030223 · Cited by 540

Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia

Haffner, D., Emma, F., Eastwood, D. M., Duplan, M. B., Bacchetta, J., Schnabel, D., Wicart, P., Böckenhauer, D., Santos, F., Levtchenko, E. N., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0152-5 · Cited by 526

Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production

David, V., Martin, A., Isakova, T., Spaulding, C., Qi, L., Ramirez, V., Zumbrennen‐Bullough, K. B., Sun, C. C., Lin, H. Y.-F., Babitt, J. L., et al. (2015) · Kidney International · doi:10.1038/ki.2015.290 · Cited by 495

The systemic nature of CKD

Zoccali, C., Vanholder, R. C., Massy, Z. A., Ortíz, A., Sarafidis, P. A., Dekker, F. W., Fliser, D., Fouque, D. P., Heine, G. H., Jager, K. J., et al. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.52 · Cited by 464

Fibroblast Growth Factor-23 and Cardiovascular Events in CKD

Scialla, J. J., Xie, H., Rahman, M., Anderson, A. H., Isakova, T., OJO, A. O., Zhang, X., Nessel, L. C., Hamano, T., Grunwald, J. E., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013050465 · Cited by 448

Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23

Degirolamo, C., Sabbà, C., & Moschetta, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.9 · Cited by 424

FGF23 neutralization improves chronic kidney disease–associated hyperparathyroidism yet increases mortality

Shalhoub, V., Shatzen, E. M., Ward, S. C., Davis, J., Stevens, J. L., Bi, V., Renshaw, L., Hawkins, N., Wang, W., Chen, C., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61405 · Cited by 417

Update on fibroblast growth factor 23 in chronic kidney disease

Wolf, M. S. (2012) · Kidney International · doi:10.1038/ki.2012.176 · Cited by 396

Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences

Panizo, S., Martínez‐Arias, L., Alonso‐Montes, C., Cannata, P., Martín-Carro, B., Martín, J. L. F., Naves‐Díaz, M., Carrillo‐López, N., & Cannata-Andía, J. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010408 · Cited by 402

KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)

Isakova, T., Nickolas, T. L., Denburg, M., Yarlagadda, S. G., Weiner, D. E., Gutiérrez, O. M., Bansal, V., Rosas, S. E., Nigwekar, S. U., Yee, J., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.07.019 · Cited by 374

Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets

Lim, Y. J., Sidor, N. A., Tonial, N. C., Che, A., & Urquhart, B. L. (2021) · Toxins · doi:10.3390/toxins13020142 · Cited by 400

Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association

Zoccali, C., Mallamaci, F., Adamczak, M., de Oliveira, R. B., Massy, Z. A., Sarafidis, P. A., Agarwal, R., Mark, P. B., Kotanko, P., Ferro, C. J., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad083 · Cited by 399

Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease

Singh, S., Grabner, A., Yanucil, C., Schramm, K. J., Czaya, B. A., Krick, S., Czaja, M. J., Bartz, R., Abraham, R., Marco, G. S. D., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.05.019 · Cited by 365

Bone and muscle: Interactions beyond mechanical

Brotto, M. A. P., & Bonewald, L. F. (2015) · Bone · doi:10.1016/j.bone.2015.02.010 · Cited by 347

The Effects of High-Protein Diets on Kidney Health and Longevity

Ko, G.-J., Rhee, C. M., Kalantar-Zadeh, K., & Joshi, S. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020010028 · Cited by 345

Secondary Osteoporosis

Ebeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 368

Arterial calcification and bone physiology: role of the bone–vascular axis

Thompson, B., & Towler, D. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.36 · Cited by 348

Fibroblast growth factor 23 is not associated with and does not induce arterial calcification

Scialla, J. J., Lau, W. L., Reilly, M. P., Isakova, T., Yang, H.-Y. L., Crouthamel, M. H., Chavkin, N. W., Rahman, M., WAHL, P. W., Amaral, A. P., et al. (2013) · Kidney International · doi:10.1038/ki.2013.3 · Cited by 339

Therapeutic management of hypophosphatemic rickets from infancy to adulthood

Linglart, A., Biosse-Duplan, M., Briot, K., Chaussain, C., Esterle, L., Guillaume-Czitrom, S., Kamenicky, P., Nevoux, J., Prié, D., Rothenbuhler, A., et al. (2014) · Endocrine Connections · doi:10.1530/ec-13-0103 · Cited by 331

Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart

Xie, J., Cha, S., An, S.-W., Kuro‐o, M., Birnbaumer, L., & Huang, C.-L. (2012) · Nature Communications · doi:10.1038/ncomms2240 · Cited by 335

Fibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-Living Individuals

Ix, J. H., Katz, R., Kestenbaum, B. R., de Boer, I. H., Chonchol, M., Mukamal, K. J., Rifkin, D. E., Siscovick, D. S., Sarnak, M. J., & Shlipak, M. G. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.040 · Cited by 326

FGF23 regulates renal sodium handling and blood pressure

Andrukhova, O., Slavić, S., Тихоновна, С. А., Zeitz, U., Shalhoub, V., Lanske, B., Pohl, E. E., & Erben, R. G. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303716 · Cited by 326

Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism

Block, G. A., Bushinsky, D. A., Cheng, S., Cunningham, J., Dehmel, B., Drüeke, T. B., Ketteler, M., Kewalramani, R., Martin, K. J., Moe, S. M., et al. (2017) · JAMA · doi:10.1001/jama.2016.19468 · Cited by 319

Associations between Kidney Function and Subclinical Cardiac Abnormalities in CKD

Park, M., Hsu, C., Li, Y., Mishra, R., Keane, M. G., Rosas, S. E., Dries, D. L., Xie, D., Chen, J., He, J., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012020145 · Cited by 318

Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho

Yamada, S., & Giachelli, C. M. (2016) · Bone · doi:10.1016/j.bone.2016.11.012 · Cited by 324

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis

Moe, S. M., Chertow, G. M., Parfrey, P. S., Kubo, Y., Block, G. A., Correa‐Rotter, R., Drüeke, T. B., Herzog, C. A., London, G. M., Mahaffey, K. W., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013876 · Cited by 305

Chronic Kidney Disease: A Clinical Model of Premature Aging

Stenvinkel, P., & Larsson, T. E. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.11.051 · Cited by 300

Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models

Su, N. Y., Jin, M. Y., & Chen, L. (2014) · Bone Research · doi:10.1038/boneres.2014.3 · Cited by 291

Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update

Roumeliotis, S. K., Mallamaci, F., & Zoccali, C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082359 · Cited by 307

FGF23 and its role in X-linked hypophosphatemia-related morbidity

Beck‐Nielsen, S. S., Zulf Mughal, M., Haffner, D., Nilsson, O., Levtchenko, E. N., Ariceta, G., Collantes, C. D. L., Schnabel, D., Jandhyala, R., & Mäkitie, O. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1014-8 · Cited by 295

Klotho and Phosphate Are Modulators of Pathologic Uremic Cardiac Remodeling

Hu, M. C., Shi, M., Cho, H. J., ADAMS-HUET, B. A., Paek, J., Hill, K., Shelton, J. M., Amaral, A. P., Faul, C., Taniguchi, M., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014050465 · Cited by 278

FGF23 signaling impairs neutrophil recruitment and host defense during CKD

Rossaint, J., Oehmichen, J., Aken, H. V., Reuter, S., Pavenstädt, H. J., Meersch, M., Unruh, M. L., & Zarbock, A. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83470 · Cited by 282

Fibroblast Growth Factor 23 and Inflammation in CKD

Mendoza, J. M., Isakova, T., Ricardo, A. C., Xie, H., Navaneethan, S. D., Anderson, A. H., Bazzano, L., Xie, D., Kretzler, M., Nessel, L. C., et al. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.13281211 · Cited by 270

Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet

Lau, W. L., Leaf, E. M., Hu, M. C., Takeno, M. M., Kuro‐o, M., Moe, O. W., & Giachelli, C. M. (2012) · Kidney International · doi:10.1038/ki.2012.322 · Cited by 266

Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy

Hu, M. C., Shi, M., Gillings, N., Flores, B., Takahashi, M., Kuro‐o, M., & Moe, O. W. (2017) · Kidney International · doi:10.1016/j.kint.2016.10.034 · Cited by 264

Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate

Xie, J., Yoon, J., An, S.-W., Kuro‐o, M., & Huang, C.-L. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014040325 · Cited by 265

High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III

Chang, A. R., Lazo, M., Appel, L. J., Gutiérrez, O. M., & Grams, M. E. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.073148 · Cited by 262

Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study

Michaëlsson, K., Melhus, H., Lemming, E. W., Wolk, A., & Byberg, L. (2013) · BMJ · doi:10.1136/bmj.f228 · Cited by 261

Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism

Kuro‐o, M. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.111 · Cited by 257

The role of phosphate in kidney disease

on behalf of the ERA–EDTA Working Group on Chronic Kidney Disease–Mineral and Bone Disorders and the European Renal Nutrition Working Group, Vervloet, M. G., Sezer, S., Massy, Z. A., Johansson, L., Cozzolino, M. G., & Fouque, D. P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.164 · Cited by 251

Vascular calcification: from pathophysiology to biomarkers

Evrard, S., Delanaye, P., Kamel, S., Cristol, J., Cavalier, E., Arnaud, J., Zaoui, P., Carlier, M.-C., Laville, M., Fouque, D. P., et al. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.08.034 · Cited by 248

Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment

Lullo, L. D., Gorini, A., Russo, D., Santoboni, A., & Ronco, C. (2015) · Cardiorenal Medicine · doi:10.1159/000435838 · Cited by 235

Interactions Between Muscle Tissues and Bone Metabolism

Kawao, N., & Kaji, H. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25040 · Cited by 235

FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2–SGK1 signaling pathway

Andrukhova, O., Zeitz, U., Goetz, R. M., Mohammadi, M., Lanske, B., & Erben, R. G. (2012) · Bone · doi:10.1016/j.bone.2012.05.015 · Cited by 228

Klotho and Chronic Kidney Disease

Hu, M. C., Kuro‐o, M., & Moe, O. W. (2013) · Contributions to nephrology · doi:10.1159/000346778 · Cited by 225

Genetic insights into the mechanisms of Fgf signalingPreprint

Brewer, J. R., Mazot, P., & Soriano, P. M. (2016) · Genes & Development · doi:10.1101/gad.277137.115 · Cited by 230

Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease

Lü, X., & Hu, M. C. (2016) · Kidney Diseases · doi:10.1159/000452880 · Cited by 220

Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction

Chirinos, J. A., Orlenko, A., Zhao, L., Basso, M., Cvijic, M. E., Li, Z., Spires, T. E., Yarde, M., Wang, Z., Seiffert, D., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.069 · Cited by 218

The chronic kidney disease — Mineral bone disorder (CKD-MBD): Advances in pathophysiology

Hruska, K. A., Sugatani, T., Agapova, O. A., & Fang, Y. (2017) · Bone · doi:10.1016/j.bone.2017.01.023 · Cited by 221

Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference

Babitt, J. L., Eisenga, M. F., Haase, V. H., Kshirsagar, A. V., Levin, A., Locatelli, F., Małyszko, J., Swinkels, D. W., Tarng, D., Cheung, M., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.020 · Cited by 222

Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease

Tonelli, M. A., Karumanchi, S. A., & Thadhani, R. (2016) · Circulation · doi:10.1161/circulationaha.115.018713 · Cited by 219

Circulating fibroblast growth factors as metabolic regulators--a critical appraisal.

Angelin, B., Larsson, T., & Rudling, M. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.11.001 · Cited by 210

Cardiovascular disease in chronic kidney disease: untying the Gordian knot

Hajhosseiny, R., Khavandi, K., & Goldsmith, D. J. A. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02954.x · Cited by 208

Therapeutics Targeting FGF Signaling Network in Human Diseases

Katoh, M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.003 · Cited by 207

New Insights into the Mechanism of Action of Soluble Klotho

Dalton, G. D., Xie, J., An, S.-W., & Huang, C. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00323 · Cited by 210

FGF23 Actions on Target Tissues—With and Without Klotho

Richter, B., & Faul, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00189 · Cited by 205

Electrolyte and Acid-Base Disorders in Chronic Kidney Disease and End-Stage Kidney Failure

Dhondup, T., & Qian, Q. (2017) · Blood Purification · doi:10.1159/000452725 · Cited by 220

Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease

Leifheit‐Nestler, M., Siemer, R. G., Flasbart, K., Richter, B., Kirchhoff, F., Ziegler, W. H., Klintschar, M., Becker, J. U., Erbersdobler, A., Aufricht, C., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv421 · Cited by 207

Coupling fibroblast growth factor 23 production and cleavage

Wolf, M. S., & White, K. E. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000447020.74593.6f · Cited by 198

Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism

Komaba, H., Taniguchi, M., Wada, A., Iseki, K., Tsubakihara, Y., & Fukagawa, M. (2015) · Kidney International · doi:10.1038/ki.2015.72 · Cited by 197

Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis

Marthi, A., Donovan, K., Haynes, R., Wheeler, D. C., Baigent, C., Rooney, C. M., Landray, M., Moe, S. M., Yang, J. M., Holland, L., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017121334 · Cited by 197

Cardiorenal syndrome: pathophysiology and potential targets for clinical management

Hatamizadeh, P., Fonarow, G. C., Budoff, M. J., Darabian, S., Kovesdy, C. P., & Kalantar‐Zadeh, K. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.279 · Cited by 205

A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model

Dai, B., David, V., Martin, A., Huang, J., Li, H., Jiao, Y., Gu, W., & Quarles, L. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044161 · Cited by 195

FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy

Touchberry, C. D., Green, T. M., Tchikrizov, V., Mannix, J. E., Mao, T. F., Carney, B. W., Girgis, M., Vincent, R. J., Wetmore, L. A., Dawn, B., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00596.2012 · Cited by 196

Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease

Scialla, J. J., & Wolf, M. S. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.49 · Cited by 201

Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes

Bacchetta, J., Sea, J. L., Chun, R. F., Lisse, T. S., Wesseling‐Perry, K., Gales, B., Adams, J. S., Salusky, I. B., & Hewison, M. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1740 · Cited by 190

Pathophysiology of calcium, phosphorus, and magnesium dysregulation in chronic kidney disease

Felsenfeld, A. J., Levine, B. S., & Rodriguez, M. (2015) · Seminars in Dialysis · doi:10.1111/sdi.12411 · Cited by 189

Klotho Protects Against Indoxyl Sulphate-Induced Myocardial Hypertrophy

Yang, K., Wang, C., Nie, L., Zhao, X., Gu, J., Guan, X., Wang, S., Xiao, T., Xu, X., He, T., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014060543 · Cited by 190

Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency

Jimbo, R., Kawakami-Mori, F., Mu, S., Hirohama, D., Majtan, B., Shimizu, Y., Yatomi, Y., Fukumoto, S., Fujita, T., & Shimosawa, T. (2013) · Kidney International · doi:10.1038/ki.2013.332 · Cited by 189

FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability

Silswal, N., Touchberry, C. D., Daniel, D., McCarthy, D. L., Zhang, S., Andresen, J. J., Stubbs, J. R., & Wacker, M. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00264.2014 · Cited by 198

Cardiorenal Syndrome

Lekawanvijit, S., Kompa, A. R., Wang, B. H., Kelly, D. J., & Krum, H. (2012) · Circulation Research · doi:10.1161/circresaha.112.278457 · Cited by 189

Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study , ,

Lutsey, P. L., Alonso, Á., Michos, E. D., Loehr, L. R., Astor, B. C., Coresh, J., & Folsom, A. R. (2014) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.085167 · Cited by 184

Klotho in Clinical Nephrology

Neyra, J. A., Hu, M. C., & Moe, O. W. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02840320 · Cited by 184

FGF23 signalling and physiology

Ho, B. B., & Bergwitz, C. (2021) · Journal of Molecular Endocrinology · doi:10.1530/jme-20-0178 · Cited by 180

Cardiorenal Syndrome

Kumar, U., Wettersten, N. W., & Garimella, P. S. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.04.001 · Cited by 193

Importance of Dietary Phosphorus for Bone Metabolism and Healthy Aging

Serna, J., & Bergwitz, C. (2020) · Nutrients · doi:10.3390/nu12103001 · Cited by 204

CKD-Induced Wingless/Integration1 Inhibitors and Phosphorus Cause the CKD–Mineral and Bone Disorder

Fang, Y., Ginsberg, C., Seifert, M. E., Agapova, O. A., Sugatani, T., Register, T. C., Freedman, B. I., Monier‐Faugere, M., Malluche, H. H., & Hruska, K. A. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013080818 · Cited by 173

Renal and Extrarenal Actions of Klotho

Hu, M. C., Kuro‐o, M., & Moe, O. W. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.12.013 · Cited by 172

FGF23-Klotho signaling axis in the kidney

Erben, R. G., & Andrukhova, O. (2016) · Bone · doi:10.1016/j.bone.2016.09.010 · Cited by 169

Klotho in health and disease

Kuro-o, M. (2012) · Current opinion in nephrology and hypertension · doi:10.1097/mnh.0b013e32835422ad · Cited by 175

Muscle‐bone crosstalk and potential therapies for sarco‐osteoporosis

Li, G., Zhang, L., Wang, D., AIQudsy, L., Jiang, J. X., Xu, H., & Shang, P. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28946 · Cited by 166

Physiological Actions of Fibroblast Growth Factor-23

Erben, R. G. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00267 · Cited by 166

Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population

Covic, A. C., Vervloet, M. G., Massy, Z. A., Ureña, P., Goldsmith, D. J. A., Brandenburg, V. M., Mazzaferro, S., Evenepoel, P., Bover, J., Apetrii, M., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30310-8 · Cited by 164

Parathyroid-Specific Deletion of Klotho Unravels a Novel Calcineurin-Dependent FGF23 Signaling Pathway That Regulates PTH Secretion

Olauson, H., Lindberg, K., Amin, R., Sato, T., Jia, T., Goetz, R. M., Mohammadi, M., Andersson, G., Lanske, B., & Larsson, T. E. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003975 · Cited by 163

Evolving concepts in the pathogenesis of uraemic cardiomyopathy

Wang, X., & Shapiro, J. I. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0101-8 · Cited by 170

Disordered FGF23 and Mineral Metabolism in Children with CKD

Portale, A. A., Wolf, M. S., Jüppner, H., Messinger, S., Kumar, J., Wesseling‐Perry, K., Schwartz, G. J., Furth, S. L., Warady, B. A., & Salusky, I. B. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05840513 · Cited by 161

Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism

Block, G. A., Bushinsky, D. A., Cunningham, J., Drüeke, T. B., Ketteler, M., Kewalramani, R., Martin, K. J., Mix, T.-C. H., Moe, S. M., Patel, U. D., et al. (2017) · JAMA · doi:10.1001/jama.2016.19456 · Cited by 161

Identification of a novel FN1–FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour

Lee, J., Jeng, Y., Su, S.-Y., Wu, C., Tsai, K., Lee, C., Lin, C., Carter, J. M., Huang, J., Chen, S., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4465 · Cited by 160

Acute Kidney Injury and Risk of Heart Failure and Atherosclerotic Events

Go, A. S., Hsu, C., Yang, J., Tan, T. C., Zheng, S., Ordoñez, J. D., & Liu, K. D. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12591117 · Cited by 159

Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease

Leifheit‐Nestler, M., Siemer, R. G., Flasbart, K., Richter, B., Kirchhoff, F., Ziegler, W. H., Klintschar, M., Becker, J. U., Erbersdobler, A., Aufricht, C., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv421 · Cited by 207

Connecting the dots on fibroblast growth factor 23 and left ventricular hypertrophy

Gutiérrez, O. M. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv445 · Cited by 5

SaO027CARDIO-PATHOLOGICAL EFFECTS OF FGF23 IN CKD ARE MEDIATED BY FGFR4

Grabner, A., Amaral, A. P., Singh, S., Schramm, K. J., Sloan, A. J., Kentrup, D., Reuter, S., Pavenstaedt, H., Marco, G. S. D., Wolf, M., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv150.04

FGF-23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD

Hidaka, N., Inoue, K., Katô, H., Hoshino, Y., Koga, M., Kinoshita, Y., Takashi, Y., Makita, N., Fukumoto, S., Nangaku, M., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100747 · Cited by 13

Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease

Gutiérrez, O. M., Januzzi, J. L., Isakova, T., Laliberte, K. A., Smith, K., Collerone, G., Sarwar, A., Hoffmann, U., Coglianese, E. E., Christenson, R. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.844506 · Cited by 843